How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about icosapent ethyl

Marketing authorisation indication

2.1 Icosapent ethyl (Vazkepa, Amarin Corporation) is indicated 'to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [1.7mmol/l]) and established cardiovascular disease or diabetes, and at least one other cardiovascular risk factor'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 Icosapent ethyl costs £173 per pack of 120 capsules (including VAT; company submission). Costs may vary in different settings because of negotiated procurement discounts.